000			03760nam a22003855i 4500
001			86110
003			ES-MaUEC
005			20240611040146.0
007			cr nn 008mamaa
008			161006s2016 gw | s |||| 0|eng d
020			_a9783319390536
040			_aES-MaUEC
050		4	_aRS431.A64 _bP43 2016 EB
082	0	4	_a615.19
245	1	0	_aPharmacokinetics in Drug Development : _bProblems and Challenges in Oncology, Volume 4 _cedited by Peter L Bonate, Danny R Howard
264		1	_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (XII, 330 páginas) _b32 ilustraciones, 23 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aOverview of Oncology Drug Development -- A Global Perspective on First-In-Man Dose Selection: Oncology and Beyond -- Controversies in Oncology: Size-Based vs. Fixed Dosing -- Clinical QTc Assessment in Oncology -- Expediting Drug Development: Breakthrough Therapy Designation -- Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors -- Combination Development -- Role of Pharmacokinetics-Pharmacodynamics in Biosimilar Assessments -- Pharmacokinetics and Pharmacogenetics of Metronomics -- Modeling Tumor Growth in Animals and Humans: an Evolutionary Approach -- Practical Considerations for Clinical Pharmacology in Oncology Drug Development: A Survey of Approvals from 2009-2015 -- New Advancements in Exposure-Response Analysis to Inform Regulatory Decision-Making .
520			_aBack cover copy In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely � to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamicconcepts for tyrosine kinases,the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist�s point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented. .
650		7	_aOncología _2embne _9139207
700	1		_aBonate, Peter L. _eeditor literario _984103 _0Local _0http://id.loc.gov/authorities/names/n00002391 _1http://viaf.org/viaf/20911002
700	1		_aHoward, Danny R. _eeditor literario _999554 _0Local _1http://viaf.org/viaf/38209770
710	2		_aSpringerLink (Online service) _0Local _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-39053-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319390536
907			_a.b1295388x _b10-10-17 _c21-11-16
942			_2lcc _cLE
945			_aEBOOK EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11614948 _z30-06-17
988	0	0	_aEBOOK, EBSPRINGER, GOBI_sep2018
988			_aEbook_one2one
998			_aSI _a_alco _a_vill _b10/2018 _cm _dz _ef _feng _ggw _h0
999			_c86110 _d86110 _x1